Extensions

For US Patent 10828345, here's a detailed breakdown of its term adjustments, extensions, family members, and projected expiration date:

Patent Term Adjustments (PTA) and Patent Term Extensions (PTE)

While the USPTO does not calculate expiration dates for patents directly, it does provide for Patent Term Adjustment (PTA) and Patent Term Extension (PTE).

• Patent Term Adjustment (PTA): Granted to compensate for administrative delays incurred during the patent's prosecution before the USPTO. The Google Patents entry for US10828345B2 does not explicitly list a specific PTA amount, but PTA is included in the "Anticipated expiration" date provided.
• Patent Term Extension (PTE): Awarded to compensate for delays incurred in obtaining regulatory approval for a patented product, especially relevant for pharmaceutical patents requiring FDA review. The Google Patents entry for US10828345B2 does not explicitly mention any PTE.

To confirm specific PTA or PTE details, one would typically need to consult the patent's file wrapper on the USPTO Patent Center.

Continuation and Divisional Applications

US Patent 10828345B2 is part of a complex family of applications. The patent explicitly states that it is a continuation of several earlier applications:

• U.S. patent application Ser. No. 15/471,506, filed Mar. 28, 2017 (now U.S. Pat. No. 10,130,681)
• U.S. patent application Ser. No. 14/972,560, filed Dec. 17, 2015 (now U.S. Pat. No. 9,669,069)
• U.S. patent application Ser. No. 13/940,370, filed Jul. 12, 2013 (now U.S. Pat. No. 9,254,338)
• International Patent Application No. PCT/US2012/020855, filed on Jan. 11, 2012
• U.S. Provisional Application No. 61/432,245, filed on Jan. 13, 2011 (this is the earliest priority date)

Additionally, the Google Patents "Priority Applications" and "Family Applications" sections list numerous other applications that claim priority from or are related to this patent:

Priority Applications (claiming priority from the earliest date of 2011-01-13):

• US16/159,282 (US10828345B2 itself)
• US16/397,267 (US10888601B2)
• US17/072,417 (US11986511B2)
• US17/112,404 (US11730794B2)
• US17/112,063 (US11975045B2)
• US17/350,958 (US11707506B2)
• US17/352,892 (US11253572B2)
• US17/740,744 (US11559564B2)
• US18/496,472 (US12268730B2)
• US19/027,212 (US20250152669A1)

Applications Claiming Priority (parent applications from which US10828345B2 claims priority):

• US15/471,506 (US10130681B2)
• US14/972,560 (US9669069B2)
• US13/940,370 (US9254338B2)
• PCT/US2012/020855 (WO2012097019A1)
• U.S. Provisional Application No. 61/432,245, filed on Jan. 13, 2011

This indicates that US10828345B2 is a continuation application in a long chain, all claiming benefit from the earliest priority date of January 13, 2011.

Related Family Members

The patent belongs to a large family of related applications, both US and international. The "Family Applications" section on Google Patents lists 14 applications, including the ones mentioned above, with similar titles related to the use of VEGF antagonists to treat angiogenic eye disorders. These include:

• US13/940,370 (US9254338B2)
• US14/972,560 (US9669069B2)
• US15/471,506 (US10130681B2)
• US16/055,847 (US10857205B2)
• US16/159,282 (US10828345B2)
• US16/397,267 (US10888601B2)
• US17/072,417 (US11986511B2)
• US17/112,063 (US11975045B2)
• US17/112,404 (US11730794B2)
• US17/350,958 (US11707506B2)
• US17/352,892 (US11253572B2)
• US17/740,744 (US11559564B2)
• US18/496,472 (US12268730B2)
• US19/027,212 (US20250152669A1)

International family members are also listed under "Country Status" on Google Patents, including applications in Europe (EP), Japan (JP), Korea (KR), China (CN), Australia (AU), Brazil (BR), Canada (CA), Hong Kong (HK), Israel (IL), Mexico (MX), Singapore (SG), and the international PCT application (WO).

Projected Expiration Date

The Google Patents entry for US10828345B2 states an "Anticipated expiration" date of 2032-01-11.

This date is likely calculated based on the standard 20-year patent term from the earliest priority date (January 13, 2011) and includes any applicable Patent Term Adjustment (PTA). The standard patent term is generally 20 years from the earliest claimed filing date of a U.S. non-provisional or PCT application from which it claims priority. Given the earliest priority date of January 13, 2011, a 20-year term would typically end on January 13, 2031. The difference between this and the anticipated expiration date of January 11, 2032, suggests approximately one year of Patent Term Adjustment.